{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Insulin+Treated+Type+2+Diabetes+Mellitus&page=2",
    "query": {
      "condition": "Insulin Treated Type 2 Diabetes Mellitus",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 166,
    "total_pages": 17,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Insulin+Treated+Type+2+Diabetes+Mellitus&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Insulin+Treated+Type+2+Diabetes+Mellitus&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-11T11:07:50.560Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04227626",
      "title": "Inpatient Closed Loop Glucose Control With the Gen 2 GlucoSTAT",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Type 1 Diabetes",
        "Type 2 Diabetes Treated With Insulin"
      ],
      "interventions": [
        {
          "name": "GlucoSTAT",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2021-04",
      "completion_date": "2021-04",
      "has_results": false,
      "last_update_posted_date": "2020-10-22",
      "last_synced_at": "2026-10-11T11:07:50.560Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04227626"
    },
    {
      "nct_id": "NCT05317585",
      "title": "Continuous Glucose Monitor Use in Pregnancy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Type 2 Diabetes Treated With Insulin",
        "Pregnancy, High Risk"
      ],
      "interventions": [
        {
          "name": "Continuous Glucose Monitor",
          "type": "DEVICE"
        },
        {
          "name": "Routine Capillary Blood Glucose Monitoring (Fingerstick Glucose)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "University of Massachusetts, Worcester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 180,
      "start_date": "2024-05-23",
      "completion_date": "2027-07-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-03",
      "last_synced_at": "2026-10-11T11:07:50.560Z",
      "location_count": 1,
      "location_summary": "Worcester, Massachusetts",
      "locations": [
        {
          "city": "Worcester",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05317585"
    },
    {
      "nct_id": "NCT00151749",
      "title": "WelChol® and Insulin in Treating Patients With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Colesevelam hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daiichi Sankyo",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 260,
      "start_date": "2004-06",
      "completion_date": "2005-12",
      "has_results": false,
      "last_update_posted_date": "2012-01-18",
      "last_synced_at": "2026-10-11T11:07:50.560Z",
      "location_count": 45,
      "location_summary": "Tuscumbia, Alabama • Sierra Vista, Arizona • Jonesboro, Arkansas + 42 more",
      "locations": [
        {
          "city": "Tuscumbia",
          "state": "Alabama"
        },
        {
          "city": "Sierra Vista",
          "state": "Arizona"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Searcy",
          "state": "Arkansas"
        },
        {
          "city": "Carmichael",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00151749"
    },
    {
      "nct_id": "NCT05259033",
      "title": "A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "IcoSema",
          "type": "DRUG"
        },
        {
          "name": "Semaglutide 1 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 683,
      "start_date": "2022-04-11",
      "completion_date": "2024-01-16",
      "has_results": true,
      "last_update_posted_date": "2026-06-12",
      "last_synced_at": "2026-10-11T11:07:50.560Z",
      "location_count": 76,
      "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 65 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City West",
          "state": "Arizona"
        },
        {
          "city": "Concord",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05259033"
    },
    {
      "nct_id": "NCT02963922",
      "title": "Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Metabolism and Nutrition Disorder",
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Liraglutide 3.0 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 396,
      "start_date": "2017-02-06",
      "completion_date": "2018-09-25",
      "has_results": true,
      "last_update_posted_date": "2020-03-30",
      "last_synced_at": "2026-10-11T11:07:50.560Z",
      "location_count": 19,
      "location_summary": "Birmingham, Alabama • Concord, California • Fresno, California + 14 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Plantation",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02963922"
    },
    {
      "nct_id": "NCT01068860",
      "title": "To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus",
        "Impaired Glucose Tolerance"
      ],
      "interventions": [
        {
          "name": "Canakinumab 150 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo to Canakinumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "18 Years to 74 Years"
      },
      "enrollment_count": 246,
      "start_date": "2010-02",
      "completion_date": "2010-08",
      "has_results": true,
      "last_update_posted_date": "2011-09-05",
      "last_synced_at": "2026-10-11T11:07:50.560Z",
      "location_count": 11,
      "location_summary": "Los Angeles, California • Santa Ana, California • Spring Valley, California + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Santa Ana",
          "state": "California"
        },
        {
          "city": "Spring Valley",
          "state": "California"
        },
        {
          "city": "Madisonville",
          "state": "Kentucky"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01068860"
    },
    {
      "nct_id": "NCT00360698",
      "title": "Insulin Glulisine in Type 2 Diabetic Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Insulin Glargine",
          "type": "DRUG"
        },
        {
          "name": "Glimepiride",
          "type": "DRUG"
        },
        {
          "name": "Insulin Glulisine",
          "type": "DRUG"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 106,
      "start_date": "2006-07",
      "completion_date": "2008-08",
      "has_results": true,
      "last_update_posted_date": "2011-08-08",
      "last_synced_at": "2026-10-11T11:07:50.560Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00360698"
    },
    {
      "nct_id": "NCT00612040",
      "title": "Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes",
        "Diabetes Mellitus, Type 1"
      ],
      "interventions": [
        {
          "name": "insulin degludec",
          "type": "DRUG"
        },
        {
          "name": "insulin glargine",
          "type": "DRUG"
        },
        {
          "name": "insulin aspart",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 178,
      "start_date": "2008-01",
      "completion_date": "2008-06",
      "has_results": true,
      "last_update_posted_date": "2017-03-03",
      "last_synced_at": "2026-10-11T11:07:50.560Z",
      "location_count": 9,
      "location_summary": "Walnut Creek, California • Honolulu, Hawaii • Idaho Falls, Idaho + 5 more",
      "locations": [
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        },
        {
          "city": "Idaho Falls",
          "state": "Idaho"
        },
        {
          "city": "Des Moines",
          "state": "Iowa"
        },
        {
          "city": "Hyattsville",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00612040"
    },
    {
      "nct_id": "NCT02060916",
      "title": "Study to Evaluate the Safety and Efficacy of PAZ320 in Patients With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 2 Diabetes Treated With Insulin"
      ],
      "interventions": [
        {
          "name": "PAZ320",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boston Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 24,
      "start_date": "2011-03",
      "completion_date": "2011-08",
      "has_results": false,
      "last_update_posted_date": "2014-02-13",
      "last_synced_at": "2026-10-11T11:07:50.560Z",
      "location_count": 1,
      "location_summary": "Jefferson, New Hampshire",
      "locations": [
        {
          "city": "Jefferson",
          "state": "New Hampshire"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02060916"
    },
    {
      "nct_id": "NCT04770532",
      "title": "A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Use Daily Insulin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Insulin degludec",
          "type": "DRUG"
        },
        {
          "name": "Insulin Icodec",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 526,
      "start_date": "2021-03-05",
      "completion_date": "2022-03-01",
      "has_results": true,
      "last_update_posted_date": "2025-12-15",
      "last_synced_at": "2026-10-11T11:07:50.560Z",
      "location_count": 38,
      "location_summary": "Buena Park, California • Encino, California • Fresno, California + 32 more",
      "locations": [
        {
          "city": "Buena Park",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04770532"
    }
  ]
}